{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:23:42Z","timestamp":1790497422489,"version":"4.1.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,5,3]],"date-time":"2008-05-03T00:00:00Z","timestamp":1209772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00392-008-0668-3","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T17:42:37Z","timestamp":1209922957000},"page":"418-431","source":"Crossref","is-referenced-by-count":131,"title":["RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection"],"prefix":"10.1007","volume":"97","author":[{"given":"Christian","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Baumh\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koon K.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,3]]},"reference":[{"key":"668_CR1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.HYP.0000159191.98140.89","volume":"45","author":"FH Bahlmann","year":"2005","unstructured":"Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D (2005) Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45:526\u2013529","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"668_CR2","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s00592-005-0180-4","volume":"42","author":"AH Barnett","year":"2005","unstructured":"Barnett AH (2005) Preventing renal complications in diabetic patients: the diabetics exposed to telmisartan and enalaprIL (DETAIL) study. Acta Diabetol 42(Suppl 1):S42\u2013S49","journal-title":"Acta Diabetol"},{"key":"668_CR3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1742-1241.2006.01274.x","volume":"61","author":"M Baumh\u00e4kel","year":"2007","unstructured":"Baumh\u00e4kel M, B\u00f6hm M (2007) Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. Int J Clin Pract 61:361\u2013366","journal-title":"Int J Clin Pract"},{"key":"668_CR4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.324.7339.699","volume":"324","author":"J Bosch","year":"2002","unstructured":"Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J (2002) Use of ramipril in preventing stroke: double blind randomised trial. BMJ 324:699\u2013702","journal-title":"BMJ"},{"key":"668_CR5","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"E Braunwald","year":"2004","unstructured":"Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351:2058\u20132068","journal-title":"N Engl J Med"},{"key":"668_CR6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"668_CR7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","volume":"115","author":"JD Brown","year":"2007","unstructured":"Brown JD, Plutzky J (2007) Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115:518\u2013533","journal-title":"Circulation"},{"key":"668_CR8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2007.03.024","volume":"154","author":"M B\u00f6hm","year":"2007","unstructured":"B\u00f6hm M, Baumh\u00e4kel M, Probstfield JL, Schmieder R, Yusuf S, Zhao F, Koon T (2007) Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ongoing telmisartan alone and in combination with ramipril global endpoint trial\/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease (ONTARGET\/TRANSCEND). Am Heart J 154:94\u2013101","journal-title":"Am Heart J"},{"key":"668_CR9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.CIR.0000021122.63813.32","volume":"106","author":"R Candido","year":"2002","unstructured":"Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, Allen TJ (2002) Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipo-protein E-deficient mice. Circulation 106:246\u2013253","journal-title":"Circulation"},{"key":"668_CR10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1006\/excr.1996.0232","volume":"226","author":"W Cheng","year":"1996","unstructured":"Cheng W, Kajstura J, Nitahara JA, Li B, Reiss K, Liu Y, Clark WA, Krajewski S, Reed JC, Olivetti G, Anversa P (1996) Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res 226:316\u2013327","journal-title":"Exp Cell Res"},{"key":"668_CR11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995\u20131003","journal-title":"Lancet"},{"key":"668_CR12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with Angiotensin II Antagonist Losartan. Lancet 360:752\u2013760","journal-title":"Lancet"},{"key":"668_CR13","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1161\/01.CIR.94.11.2756","volume":"94","author":"F Diet","year":"1996","unstructured":"Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ (1996) Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94:2756\u20132767","journal-title":"Circulation"},{"key":"668_CR14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","volume":"45","author":"TW Doulton","year":"2005","unstructured":"Doulton TW, He FJ, Macgregor GA (2005) Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45:880\u2013886","journal-title":"Hypertension"},{"key":"668_CR15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/0002-8703(91)90694-D","volume":"121","author":"V Dzau","year":"1991","unstructured":"Dzau V, Braunwald E (1991) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121:1244\u20131263","journal-title":"Am Heart J"},{"key":"668_CR16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/00003495-200565060-00005","volume":"65","author":"R D\u00fcsing","year":"2005","unstructured":"D\u00fcsing R (2005) Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 65:773\u2013786","journal-title":"Drugs"},{"key":"668_CR17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201\u2013207","journal-title":"Lancet"},{"key":"668_CR18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0895-7061(00)01214-0","volume":"14","author":"R Fogari","year":"2001","unstructured":"Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L (2001) Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 14:27\u201331","journal-title":"Am J Hypertens"},{"key":"668_CR19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782\u2013788","journal-title":"Lancet"},{"key":"668_CR20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00392-006-0334-6","volume":"95","author":"EB Friedrich","year":"2006","unstructured":"Friedrich EB, Teo KK, B\u00f6hm M (2006) ACE inhibition in secondary prevention: are the results controversial? Clin Res Cardiol 95:61\u201367","journal-title":"Clin Res Cardiol"},{"key":"668_CR21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.0000047041.66447.29","volume":"107","author":"RJ Gibbons","year":"2003","unstructured":"Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O\u2019Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr (2003) ACC\/AHA 2002 guideline update for the management of patients with chronic stable angina\u2014summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 107:149\u2013158","journal-title":"Circulation"},{"key":"668_CR22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772\u2013776","journal-title":"Lancet"},{"key":"668_CR23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahl\u00f6f B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611\u2013616","journal-title":"Lancet"},{"key":"668_CR24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253\u2013259","journal-title":"Lancet"},{"key":"668_CR25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00392-007-0488-x","volume":"96","author":"UC Hoppe","year":"2007","unstructured":"Hoppe UC (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? Clin Res Cardiol 96:196\u2013198","journal-title":"Clin Res Cardiol"},{"key":"668_CR26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/01.CIR.103.5.630","volume":"103","author":"S Hoshida","year":"2001","unstructured":"Hoshida S, Kato J, Nishino M, Egami Y, Takeda T, Kawabata M, Tanouchi J, Yamada Y, Kamada T (2001) Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 103:630\u2013633","journal-title":"Circulation"},{"key":"668_CR27","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.553370","volume":"112","author":"SA Hunt","year":"2005","unstructured":"Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B (2005) ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112:e154\u2013e235","journal-title":"Circulation"},{"issue":"Suppl 1","key":"668_CR28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000047282","volume":"91","author":"S Julius","year":"1999","unstructured":"Julius S (1999) Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan antihypertensive long-term use evaluation. Cardiology 91(Suppl 1):8\u201313","journal-title":"Cardiology"},{"key":"668_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3317\/jraas.2004.006","volume":"5","author":"R Komers","year":"2004","unstructured":"Komers R, Simkova R, Kazdova L, Ruzickova J, Pelikanova T (2004) Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to l-arginine in Type 1 diabetes. J Renin Angiotensin Aldosterone Syst 5:33\u201338","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"668_CR30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejheart.2004.09.005","volume":"6","author":"H Krum","year":"2004","unstructured":"Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN (2004) Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 6:937\u2013945","journal-title":"Eur J Heart Fail"},{"key":"668_CR31","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI316","volume":"101","author":"A Leri","year":"1998","unstructured":"Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anversa P (1998) Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101:1326\u20131342","journal-title":"J Clin Invest"},{"key":"668_CR32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"668_CR33","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI119730","volume":"100","author":"Q Li","year":"1997","unstructured":"Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P (1997) Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 100:1991\u20131999","journal-title":"J Clin Invest"},{"key":"668_CR34","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.jacc.2003.10.073","volume":"43","author":"E Lonn","year":"2004","unstructured":"Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan B, Tanser P, Magi A, Yusuf S (2004) Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the heart outcomes prevention evaluation (HOPE) trial. J Am Coll Cardiol 43:2200\u20132206","journal-title":"J Am Coll Cardiol"},{"key":"668_CR35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.RES.85.2.137","volume":"85","author":"R Malhotra","year":"1999","unstructured":"Malhotra R, Sadoshima J, Brosius FC III, Izumo S (1999) Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro. Circ Res 85:137\u2013146","journal-title":"Circ Res"},{"key":"668_CR36","first-page":"1462","volume":"28","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O\u2019Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL (2007) Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462\u20131536","journal-title":"Eur Heart J"},{"key":"668_CR37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 100:1056\u20131064","journal-title":"Circulation"},{"key":"668_CR38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767\u2013771","journal-title":"Lancet"},{"key":"668_CR39","doi-asserted-by":"crossref","unstructured":"McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Kober L, Van de WF, Califf R, Pfeffer M (2006) The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in acute myocardial infarction trial (VALIANT). J Am Coll Cardiol 47:726\u2013733","DOI":"10.1016\/j.jacc.2005.09.055"},{"key":"668_CR40","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/HJH.0b013e3282ef45e9","volume":"25","author":"J Menard","year":"2007","unstructured":"Menard J, Azizi M (2007) The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 25:1775\u20131782","journal-title":"J Hypertens"},{"key":"668_CR41","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(07)60669-2","volume":"369","author":"S Mochizuki","year":"2007","unstructured":"Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N (2007) Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369:1431\u20131439","journal-title":"Lancet"},{"key":"668_CR42","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/BF03349207","volume":"29","author":"R Negro","year":"2006","unstructured":"Negro R, Formoso G, Hassan H (2006) The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 29:957\u2013961","journal-title":"J Endocrinol Invest"},{"key":"668_CR43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/hc0302.102618","volume":"105","author":"G Nickenig","year":"2002","unstructured":"Nickenig G, Harrison DG (2002) The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 105:393\u2013396","journal-title":"Circulation"},{"key":"668_CR44","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/hc0402.102619","volume":"105","author":"G Nickenig","year":"2002","unstructured":"Nickenig G, Harrison DG (2002) The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation 105:530\u2013536","journal-title":"Circulation"},{"key":"668_CR45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00004872-198406000-00010","volume":"2","author":"H Okunishi","year":"1984","unstructured":"Okunishi H, Miyazaki M, Toda N (1984) Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 2:277\u2013284","journal-title":"J Hypertens"},{"key":"668_CR46","unstructured":"Parving HH (2007) AVOID: Aliskiren in the evaluation of proteinuria in diabetes. American Society of Nephrology Renal Week Oral Presentation, Poster SA-P01051"},{"key":"668_CR47","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870\u2013878","journal-title":"N Engl J Med"},{"key":"668_CR48","unstructured":"Pepine CJ, Probstfield JL (2004) A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients, CME monograph, UF College of Medicine. Vasc Biol Clin Pract 6"},{"key":"668_CR49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.CIR.104.2.191","volume":"104","author":"F Perticone","year":"2001","unstructured":"Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G (2001) Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104:191\u2013196","journal-title":"Circulation"},{"key":"668_CR50","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de WF, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893\u20131906","journal-title":"N Engl J Med"},{"key":"668_CR51","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0002-9149(01)01461-8","volume":"87","author":"B Pitt","year":"2001","unstructured":"Pitt B, O\u2019Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS (2001) The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 87:1058\u20131063","journal-title":"Am J Cardiol"},{"key":"668_CR52","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582\u20131587","journal-title":"Lancet"},{"key":"668_CR53","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"Progress collaborative group","year":"2001","unstructured":"Progress collaborative group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033\u20131041","journal-title":"Lancet"},{"key":"668_CR54","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1016\/S0002-9343(98)00209-5","volume":"105","author":"AA Quyyumi","year":"1998","unstructured":"Quyyumi AA (1998) Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 105:32S\u201339S","journal-title":"Am J Med"},{"key":"668_CR55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10557-007-6069-4","volume":"21","author":"A Recio-Mayoral","year":"2007","unstructured":"Recio-Mayoral A, Kaski JC, McMurray JJ, Horowitz J, van Veldhuisen DJ, Remme WJ (2007) Clinical Trials Update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther 21:459\u2013465","journal-title":"Cardiovasc Drugs Ther"},{"key":"668_CR56","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941\u20131951","journal-title":"N Engl J Med"},{"key":"668_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.RES.76.1.1","volume":"76","author":"J Sadoshima","year":"1995","unstructured":"Sadoshima J, Qiu Z, Morgan JP, Izumo S (1995) Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kDa S6 kinase in cardiac myocytes. The critical role of Ca(2+)-dependent signaling. Circ Res 76:1\u201315","journal-title":"Circ Res"},{"key":"668_CR58","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/0092-8674(93)90541-W","volume":"75","author":"J Sadoshima","year":"1993","unstructured":"Sadoshima J, Xu Y, Slayter HS, Izumo S (1993) Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75:977\u2013984","journal-title":"Cell"},{"key":"668_CR59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.jhh.1002161","volume":"21","author":"R Scaglione","year":"2007","unstructured":"Scaglione R, Argano C, Di Chiara T, Parrinello G, Colomba D, Avellone G, Donatelli M, Corrao S, Licata G (2007) Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients. J Hum Hypertens 21:307\u2013315","journal-title":"J Hum Hypertens"},{"key":"668_CR60","first-page":"1355","volume":"99","author":"JH Schefe","year":"2006","unstructured":"Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, Ruiz P, Unger T, Funke-Kaiser H (2006) A novel signal transduction cascade involving direct physical interaction of the renin\/prorenin receptor with the transcription factor promyelocytic zinc finger protein. CircRes 99:1355\u20131366","journal-title":"CircRes"},{"key":"668_CR61","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/01.CIR.101.12.1372","volume":"101","author":"B Schieffer","year":"2000","unstructured":"Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H (2000) Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101:1372\u20131378","journal-title":"Circulation"},{"key":"668_CR62","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/01.hjh.0000220101.57896.cd","volume":"24","author":"RE Schmieder","year":"2006","unstructured":"Schmieder RE (2006) Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J Hypertens Suppl 24:S31\u2013S35","journal-title":"J Hypertens Suppl"},{"key":"668_CR63","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","volume":"369","author":"RE Schmieder","year":"2007","unstructured":"Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM (2007) Renin-angiotensin system and cardiovascular risk. Lancet 369:1208\u20131219","journal-title":"Lancet"},{"key":"668_CR64","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00392-007-0510-3","volume":"96","author":"RE Schmieder","year":"2007","unstructured":"Schmieder RE, Schrader J, Zidek W, Tebbe U, Paar WD, Bramlage P, Pittrow D, B\u00f6hm M (2007) Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 96:247\u2013257","journal-title":"Clin Res Cardiol"},{"key":"668_CR65","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.2337\/diabetes.54.12.3442","volume":"54","author":"M Schupp","year":"2005","unstructured":"Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54:3442\u20133452","journal-title":"Diabetes"},{"key":"668_CR66","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjhyper.2007.04.001","volume":"20","author":"JE Sealey","year":"2007","unstructured":"Sealey JE, Laragh JH (2007) Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 20:587\u2013597","journal-title":"Am J Hypertens"},{"issue":"Suppl 1","key":"668_CR67","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1007\/s00592-005-0181-3","volume":"42","author":"P Sleight","year":"2005","unstructured":"Sleight P (2005) The ONTARGET\/TRANSCEND trial programme: baseline data. Acta Diabetol 42(Suppl 1):S50\u2013S56","journal-title":"Acta Diabetol"},{"key":"668_CR68","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1161\/CIRCULATIONAHA.104.508093","volume":"111","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA (2005) Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 111:3411\u20133419","journal-title":"Circulation"},{"key":"668_CR69","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","volume":"26","author":"UM Steckelings","year":"2005","unstructured":"Steckelings UM, Kaschina E, Unger T (2005) The AT2 receptor\u2013a matter of love and hate. Peptides 26:1401\u20131409","journal-title":"Peptides"},{"key":"668_CR70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cmet.2006.12.007","volume":"5","author":"UM Steckelings","year":"2007","unstructured":"Steckelings UM, Rettig R, Unger T (2007) Angiotensin in the kidney: a key to understanding hypertension? Cell Metab 5:7\u20138","journal-title":"Cell Metab"},{"key":"668_CR71","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.CIR.101.13.1586","volume":"101","author":"WB Strawn","year":"2000","unstructured":"Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM (2000) Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 101:1586\u20131593","journal-title":"Circulation"},{"key":"668_CR72","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1210\/jc.2003-031012","volume":"89","author":"KC Tan","year":"2004","unstructured":"Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, Lam KS (2004) Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 89:765\u2013769","journal-title":"J Clin Endocrinol Metab"},{"key":"668_CR73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","volume":"148","author":"K Teo","year":"2004","unstructured":"Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H (2004) Rationale, design, and baseline characteristics of two large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials. Am Heart J 148:52\u201361","journal-title":"Am Heart J"},{"key":"668_CR74","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","unstructured":"The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429\u20131435","journal-title":"N Engl J Med"},{"key":"668_CR75","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMe0801925","volume":"358","author":"S Yusuf","year":"2008","unstructured":"ONTARGET Investigators, Yusuf S, Teo KK, Poque Y, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N EnglJ Med 358:1615\u20131616","journal-title":"N EnglJ Med"},{"key":"668_CR76","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713\u2013720","journal-title":"BMJ"},{"key":"668_CR77","doi-asserted-by":"crossref","first-page":"25J","DOI":"10.1016\/j.amjcard.2007.05.011","volume":"100","author":"T Unger","year":"2007","unstructured":"Unger T, Stoppelhaar M (2007) Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol 100:25J\u201331J","journal-title":"Am J Cardiol"},{"key":"668_CR78","doi-asserted-by":"crossref","unstructured":"Van dH I, Voors AA, van Veldhuisen DJ (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? Clin Res Cardiol 96:193\u2013195","DOI":"10.1007\/s00392-007-0487-y"},{"key":"668_CR79","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672\u2013678","journal-title":"Circulation"},{"key":"668_CR80","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1161\/01.CIR.99.15.2027","volume":"99","author":"A Warnholtz","year":"1999","unstructured":"Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, B\u00f6hm M, Meinertz T, Munzel T (1999) Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99:2027\u20132033","journal-title":"Circulation"},{"key":"668_CR81","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.hjh.0000220402.53869.72","volume":"24","author":"S Wassmann","year":"2006","unstructured":"Wassmann S, Nickenig G (2006) Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl 24:S15\u2013S21","journal-title":"J Hypertens Suppl"},{"key":"668_CR82","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00004872-200307006-00007","volume":"21","author":"M Weber","year":"2003","unstructured":"Weber M (2003) The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens Suppl 21:S37\u2013S46","journal-title":"J Hypertens Suppl"},{"key":"668_CR83","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/01.RES.77.2.258","volume":"77","author":"T Yamazaki","year":"1995","unstructured":"Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, Takano H, Hiroi Y, Ueki K, Tobe K (1995) Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res 77:258\u2013265","journal-title":"Circ Res"},{"key":"668_CR84","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/138920106776597685","volume":"7","author":"EH Yao","year":"2006","unstructured":"Yao EH, Yu Y, Fukuda N (2006) Oxidative stress on progenitor and stem cells in cardiovascular diseases. Curr Pharm Biotechnol 7:101\u2013108","journal-title":"Curr Pharm Biotechnol"},{"key":"668_CR85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145\u2013153","journal-title":"N Engl J Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-008-0668-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-008-0668-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-008-0668-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:21:53Z","timestamp":1559046113000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-008-0668-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,3]]},"references-count":85,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1007\/s00392-008-0668-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,3]]}}}